कंपनी का अवलोकन
BioMarin Pharmaceutical Inc. is a biotechnology enterprise dedicated to the development and commercialization of novel therapies designed to address life-threatening rare diseases and various medical conditions across global markets including the United States, Europe, Latin America, the Middle East, Asia Pacific, and internationally. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, an environment characterized by high regulatory standards and significant research and development expenditures aimed at creating proprietary treatments. As of the latest available data, the firm holds a market capitalization of $10.83B and generates annual revenue of $3.22B, employing a workforce of 3221 individuals to support its extensive product pipeline and operational infrastructure. These valuation and revenue metrics indicate that BioMarin has established a substantial presence in the rare disease landscape, positioning it as a significant player capable of sustaining operations and funding future innovation without reliance on external financing for daily expenses.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $3.22B, resulting in a net income of $348.90M and an EBITDA of $722.89M, which highlights a substantial gap between top-line sales and bottom-line profit due to significant operating costs and expenses inherent in the biotechnology sector. This structure reveals that while the company generates considerable gross earnings, a considerable portion of revenue is consumed by research, development, and general administrative costs before reaching the net income figure. BioMarin maintains a robust free cash flow of $402.66M, indicating strong financial flexibility that allows the company to fund capital expenditures, invest in clinical trials, or pursue strategic acquisitions without needing to raise additional equity or debt capital. The firm's profitability is reflected in a gross margin of 52.8%, an operating margin of 22.5%, and a profit margin of 10.8%, suggesting that while the cost of goods sold is managed effectively, operational efficiencies are necessary to convert revenue into net profit at a moderate rate. On the balance sheet, the company holds $1.56B in cash against $642.87M in debt, with a debt-to-equity ratio of 10.56, presenting a complex picture where the absolute cash position exceeds total debt despite the elevated leverage ratio relative to equity. Short-term liquidity appears secure given a current ratio of 5.21, which suggests the company possesses more than five times the current assets needed to cover its current liabilities. Furthermore, the return on equity stands at 5.9% and return on assets at 5.6%, metrics that indicate management's effectiveness in generating returns on the shareholders' capital and the total asset base, respectively, though these percentages reflect the capital-intensive nature of biotechnology development.
मूल्यांकन आकलन
The stock carries a trailing P/E ratio of 31.28 compared to a forward P/E of 8.36, a significant disparity that implies the market expects earnings to increase substantially in the future or that current earnings are depressed by one-time costs related to clinical development or restructuring. The price-to-book ratio is recorded at 1.78, indicating that the market values the company at a premium of 78% over its book value, reflecting the intangible value of its intellectual property, patent portfolios, and future revenue potential from its rare disease therapies. Alternative valuation metrics such as a price-to-sales ratio of 3.36 and an EV/EBITDA of 13.71 provide additional context, suggesting that the company is priced based on future sales growth expectations rather than current profitability alone. Regarding trading ranges, the 52-week high is $66.28 and the 52-week low is $50.76; without a specific current price provided in the facts, the relative position within this range cannot be calculated, but the wide band suggests volatility or stability depending on the current trading level. The beta value is 0.29, which indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting it behaves as a defensive asset that moves less than 10% for every 10% movement in the overall market index.
Growth & Income
The company is demonstrating robust expansion with a revenue growth rate of 17.0% year-over-year, while earnings growth data is listed as N/A, meaning that the expansion of sales has not yet fully translated into proportional earnings growth or that the earnings figure is not currently available for year-over-year comparison. In the absence of earnings growth data, it is observed that the company prioritizes reinvesting its substantial free cash flow and revenue into its drug development pipeline rather than distributing dividends to shareholders. Consequently, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which is a common strategy for biotechnology firms to conserve cash for high-risk, high-reward research projects. The overall growth and income profile is characterized by aggressive top-line expansion funded by internal cash generation, with the company foregoing current income distribution to accelerate the commercialization of its therapies for rare diseases.